Medical devices, healthcare technology and the business of care
FDA RECALL RECORD · Z-1084-2026

Asserachrom HPIA. Recall

Asserachrom HPIA. Model/Catalog Number: 00615. The Asserachrom HPIA kit is intended for the qualitative detection in plasma or serum of the anti-heparin-platelet factor 4 (PF4) antibodies generated during the type II heparin-induced thrombocytopenia (HIT type II) by ELISA.

FDA recall Class II

Ongoing

FDA lists this Class II recall for Asserachrom HPIA.. Review the affected identifiers, reported reason and manufacturer instructions below.

Recall at a glance

Recall number
Z-1084-2026
Recall classification
Class II
Enforcement status
Ongoing
Initiation date
Dec 15, 2025
FDA report date
Jan 21, 2026
Quantity in commerce
438 units
Distribution
See key details
FDA cause
Under Investigation by firm

What is being recalled?

Asserachrom HPIA. Model/Catalog Number: 00615. The Asserachrom HPIA kit is intended for the qualitative detection in plasma or serum of the anti-heparin-platelet factor 4 (PF4) antibodies generated during the type II heparin-induced thrombocytopenia (HIT type II) by ELISA.

Affected model & UDI checker

Search the exact identifiers published for Z-1084-2026.

The lookup covers structured identifiers listed on this page. A full UDI may also contain lot or serial information; a GTIN match alone does not check those conditions.

Affected products

Model / catalog numberProductLot scope reportedUDI / GTIN
00615Asserachrom HPIA.Check source noticeNot specified
Not specifiedAsserachrom HPIA.Check source notice03607450006155
FDA code information

Reference Number: 00615. UDI: (01)03607450006155(11)240531(17)260531(10)271288(241)00615. Lot Number: 271288.

View the original FDA recall notice

Why was this product recalled?

Potential for defect for Asserachrom HPIA lot 271288, which can affect every well in the impacted strip and produce negative results.

These are potential consequences described in the source. The recall reason does not establish how many injuries or incidents occurred.

What actions did Diagnostica Stago, Inc. take?

Diagnostica Stago notified consignees of the recall on about 12/15/2025 via email. Consignees were instructed to stop using Lot 271288 and dispose of all remaining product according to local regulations, and complete, sign, and return the attached Acknowledgement Form provided. Additionally, consignees were instructed that if they have distributed the affected lot to any other laboratory, please notify those recipients of this recall and ask them to complete and return an Acknowledgement Form.

Read the manufacturer action recorded by FDA

Recall timeline

  1. Recall initiated by firm

  2. FDA notice posted

  3. FDA classification recorded

  4. FDA enforcement report date

Related FDA submissions

No submission number with an exact verified relationship is linked in the retrieved recall notice.

FDA’s notice explicitly links the submission numbers shown here. Read each filing for its own recorded device and scope.

Source and update history

  1. FDA enforcement data

    First stored snapshot of this source.

  2. FDA device-recall notice

    First stored snapshot of this source.

The history starts with the versions held by MedtechLedger. Earlier source changes are not reconstructed. Official dates and recorded status come from FDA; page summaries describe the source information.

Our data sources and methodology